EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immunosuppressive JAG2 + tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells

Chenyang Wang iD, Moran Yang, Yujing Zhong, Kankan Cao, Xueling Wang, Chen Zhang, Yiying Wang, Mengdi He, Jiaqi Lu, Guodong Zhang, Yan Huang, Haiou Liu iD

Cancer Communications · 2025-07 · 45 (7) · 747-773

DOI: 10.1002/cac2.70021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 22.03.2025. Verfasst von Chenyang Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. Chin…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, T-Lymphocytes, Regulatory, Jagged-2 Protein, Neutrophils. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Shanghai Science and Technology Innovation Action Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumor‐associated neutrophils (TANs) play a critical role in modulating immune responses and exhibit significant heterogeneity. Our previous study demonstrated that jagged canonical Notch ligand 2 (JAG2) + TANs were associated with an immunosuppressive microenvironment in high‐grade serous ovarian cancer (HGSOC), but the underlying mechanism remains unclear. This study aimed to elucidate the role of JAG2 + TANs in tumor immunosuppressive microenvironment in HGSOC.

Methods

HGSOC samples were collected, with 274 samples constituting two independent cohorts (training and validation cohorts) and an additional 30 samples utilized to establish patient‐derived tumor organoids (PDTOs). We characterized the number and phenotype of JAG2 + TANs by multiplex immunohistochemistry, flow cytometry, and single‐cell RNA sequencing (scRNA‐seq). We investigated the biological functions of JAG2 in immune evasion using in vitro co‐culture systems, flow cytometry, tumor‐bearing mouse models, and PDTOs.

Results

JAG2 + TANs expressed elevated levels of immunosuppressive molecules, including programmed cell death ligand 1 and CD14, and had independent prognostic value for the overall survival of patients with HGSOC. scRNA‐seq analysis revealed that JAG2 + TANs exhibited a terminally mature phenotype. The infiltration of JAG2 + TANs was positively correlated with the abundance of effector regulatory T cells (eTregs). Interaction with JAG2 + TANs skewed CD4 + T cells towards an eTreg phenotype, a process that was suppressed by the Notch inhibitor LY3039478 and induced by recombinant Jagged2. Furthermore, we demonstrated that JAG2 + TANs enhanced Notch signaling activation, ultimately promoting recombination signal binding protein for immunoglobulin kappa J region (RBPJ)‐induced differentiation of naïve CD4 + T cells into eTregs. Clinically, JAG2 + TANs could serve as a biomarker for assessing immunotherapy resistance in various solid tumors. Pharmacological targeting of Notch signaling with LY3039478 or JAG2 neutralization antibodies enhanced the efficacy of programmed cell death protein 1 (PD‐1) monoclonal antibodies (mAbs) in both xenograft and PDTO models.

Conclusions

The emergence of JAG2 + TANs is crucial for the differentiation of eTregs, which triggers immune evasion and resistance to anti‐PD‐1 therapy. Inhibiting Notch signaling with LY3039478 or JAG2 neutralization antibodies may overcome this anti‐PD‐1 resistance in HGSOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsT-Lymphocytes, RegulatoryJagged-2 ProteinNeutrophilsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHumansFemaleAnimalsMiceTumor MicroenvironmentCell DifferentiationCell Line, Tumor

Stichwörter der Autor:innen

Jagged2Tumor‐associated neutrophilseffector regulatory T cellshigh‐grade serous ovarian cancerprogrammed cell death 1

Substanzen

Jagged-2 ProteinJAG2 protein, humanImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.
  • Department of Gynecologic Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, P. R. China.
  • Department of Gynecologic Oncology, Shanghai Cancer Center, Fudan University, Shanghai, P. R. China.

ORCID-Profile: Chenyang Wang, Haiou Liu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shanghai
  • Shanghai Science and Technology Innovation Action Plan
  • Shanghai Clinical Research Center for Gynecological Diseases
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Wang, C., Yang, M., Zhong, Y., Cao, K., Wang, X., Zhang, C., Wang, Y., He, M., Lu, J., Zhang, G., Huang, Y., & Liu, H. (2025). Immunosuppressive JAG2 + tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells. Cancer Communications, 45(7), 747-773. https://doi.org/10.1002/cac2.70021

Vancouver

Wang C, Yang M, Zhong Y, Cao K, Wang X, Zhang C, et al. Immunosuppressive JAG2 + tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells. Cancer Communications. 2025;45(7):747-773. doi:10.1002/cac2.70021

BibTeX
@article{Wang2025,
  author = {Wang, Chenyang and Yang, Moran and Zhong, Yujing and Cao, Kankan and Wang, Xueling and Zhang, Chen and Wang, Yiying and He, Mengdi and Lu, Jiaqi and Zhang, Guodong and Huang, Yan and Liu, Haiou},
  title = {Immunosuppressive JAG2 + tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells},
  journal = {Cancer Communications},
  year = {2025},
  volume = {45},
  number = {7},
  pages = {747--773},
  doi = {10.1002/cac2.70021}
}
Kostenlos starten →